254882-14-9 Usage
Uses
Used in Pharmaceutical Industry:
(2S,4S)-1-tert-butyl 2-methyl-4-hydroxypiperidine-1,2-dicarboxylate is used as a medication for the treatment of erectile dysfunction and benign prostatic hyperplasia. It functions by increasing blood flow to the penis, leading to improved erectile function during sexual stimulation.
Used in Pulmonary Arterial Hypertension Treatment:
In an off-label application, (2S,4S)-1-tert-butyl 2-methyl-4-hydroxypiperidine-1,2-dicarboxylate is used for the treatment of pulmonary arterial hypertension, a condition characterized by high blood pressure in the arteries that supply the lungs.
Used in Patient Care:
(2S,4S)-1-tert-butyl 2-methyl-4-hydroxypiperidine-1,2-dicarboxylate is used as a therapeutic agent to improve the quality of life for patients suffering from erectile dysfunction and other related conditions, by providing a safe and effective treatment option under medical supervision.
Check Digit Verification of cas no
The CAS Registry Mumber 254882-14-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,4,8,8 and 2 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 254882-14:
(8*2)+(7*5)+(6*4)+(5*8)+(4*8)+(3*2)+(2*1)+(1*4)=159
159 % 10 = 9
So 254882-14-9 is a valid CAS Registry Number.
InChI:InChI=1/C12H21NO5/c1-12(2,3)18-11(16)13-6-5-8(14)7-9(13)10(15)17-4/h8-9,14H,5-7H2,1-4H3/t8-,9-/m0/s1
254882-14-9Relevant academic research and scientific papers
QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS
-
Page/Page column 79-82, (2008/06/13)
The invention concerns quinazoline derivatives of the Formula (I), or pharmaceutically acceptable salts thereof: I wherein each of R1, R2, R3, R4 and m are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula (I) are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, particularly EGFR tyrosine kinase.
